Apoptosis by anthracyclines at therapeutic concentrations in MDR1+ human leukemic cells

Advances in Experimental Medicine and Biology

Volumn 457, Issue , 1999, Pages 313-324

  Chiodini, Barbara ^a   Bassan, Renato ^a   Barbui, Tiziano ^a  

^a OSPEDALI RIUNITI   (Italy)

Author keywords

Anthracyclines; Apoptosis; MDR1

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; DAUNORUBICIN; DRUG DERIVATIVE; GLYCOPROTEIN P; IDARUBICIN; IDARUBICINOL; LIPOCORTIN 5; MEMBRANE LIPID; PHOSPHATIDYLSERINE;

APOPTOSIS; ARTICLE; CELL CULTURE; CELL MEMBRANE; COMPARATIVE STUDY; DRUG EFFECT; FLOW CYTOMETRY; GENE; HUMAN; METABOLISM; MULTIDRUG RESISTANCE; NECROSIS; PHYSIOLOGY; T CELL LEUKEMIA;

ANNEXIN A5; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CELL MEMBRANE; DAUNORUBICIN; DRUG RESISTANCE, MULTIPLE; FLOW CYTOMETRY; GENES, MDR; HUMANS; IDARUBICIN; LEUKEMIA, T-CELL, ACUTE; MEMBRANE LIPIDS; NECROSIS; P-GLYCOPROTEIN; PHOSPHATIDYLSERINES; TUMOR CELLS, CULTURED;

EID: 0032620102     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-4811-9_34     Document Type: Article

References (19)

1. Hannun YA. Apoptosis and the dilemma of cancer chemotherapy. Blood 89: 1845-1853, 1997.
2. Speth PAJ, Minderman H, Haanen C: Idarubicin v daunorubicin: preclinical and clinical pharmacokinetic studies. Semin Oncol 16: 2-9, 1989 (suppl 2).
3. Ames MA, Spreafico F: Selected pharmacologic characteristics of idarubicin and idarubicinol. Leukemia 6: 70-75, 1992 (suppl 1).
4. Wheatley K: Meta-analysis of randomized trials of idarubicin (IDAR) or mitozantrone (MITO) versus daunorubicin (DNR) as induction therapy for acute myeloid leukemia (AML). Blood 86: 434a, 1995 (suppl 1, abstr).
5. Bassan R, Barbui T: Remission induction therapy for adults with acute myelogenous leukemia: towards the ICE age? Haematologica 80: 82-90, 1995.
6. Ross D, Tong Y, Cornblatt B: Idarubicin (IDA) is less vulnerable to transport-mediated multidrug resistance (MDR) than its metabolite idarubicinol (IDAol) or daunorubicin (DNR). Blood 82:257a, 1993 (suppl 1, abstr 1015).
7. Berman E, McBride M: Comparative cellular pharmacology of daunorubicin and idarubicin in human multidrug-resistant leukemia cells. Blood 79: 3267-3273, 1992.
8. Chiodini B, Bassan R, Borleri G, Lerede T, Barbui T. Idarubicin activity against multidrug resistant (mdr1+) cells is increased by cyclosporin A. In: Hiddemann W et al (eds.) Acute Leukemias VII. Springer, Berlin 1998, pp. 475-482.
9. - cases. Blood 86: 2329-2342, 1995.
10. Reid JM, Pendergrass TW, Krailo MD, Hammond GD, Ames MM: Plasma pharmacokinetics and cerebrospinal fluid concentrations of idarubicin and idarubicinol in pediatric leukemia patients. A Childrens Cancer Study Group report. Cancer Res 50: 6525-6528, 1990.
11. List AF, Speier C, Greer J, et al: Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J Clin Oncol 11: 1652-1660, 1993.
12. Koopman G, Reutelingsperger CPM, Kuijten GAM, et al: Annexin V for flow cytometric detection of phosphatidylserine expression on B cells undergoing apoptosis. Blood 84: 1415-1420, 1994.
13. Kokenberg E, Sonneveld P, Delwel R, et al: In vivo uptake of daunorubicin by acute myeloid leukemia (AML) cells measured by flow cytometry. Leukemia 2: 511-517, 1988.
14. List AF: The role of multidrug resistance and its pharmacological modulation in acute myeloid leukemia. Leukemia 10: S46-S51, 1996 (suppl 2).
15. Solary E, Caillot D, Chauffert B, et al: Feasibility of using quinine, a potential multidrug resistance-reversing agent, in combination with mitoxantrone and cytarabine for the treatment of acute leukemia. J Clin Oncol 10: 1730-1736, 1992.
16. Kornblau SM, Estey E, Madden T, et al: Phase I study of mitoxantrone plus etoposide with multidrug blockade by SDZ PSC-833 in relapsed or refractory acute myelogenous leukemia. J Clin Oncol 15: 1796-1802, 1997.
17. Ito C, Ribeiro RC, Behm FG, Raimondi SC, Pui C-H, Campana C. Cyclosporin A induces apoptosis in childhood acute lymphoblastic leukemia cells. Blood 91: 1001-1007, 1998.
18. Ross DD, Wooten PJ, Tong Y, et al: Synergistic reversal of multidrug-resistance phenotype in acute myeloid leukemia by cyclosporin A and cremophor EL. Blood 83: 1337-1347, 1994.
19. Weiss M, Maslak P, Megherian L, Scheinberg D. A phase I trial of a single high dose of idarubicin combined with high dose cytarabine (ARA-C) as induction therapy in relapsed and refractory adult patients with acute lymphoblastic leukemia (ALL). Blood 86: 786a, 1995 (suppl 1, abstr 3131).